Published in Oncology Business Week, July 25th, 2004
"The tumor necrosis factor alpha (TNF-alpha) inhibitors etanercept and infliximab have shown good clinical results in the treatment of rheumatoid arthritis and other autoimmune disorders," rheumatologists in Switzerland noted. "With these novel fusion proteins, immune-mediated side effects, among them various cutaneous reactions, have been encountered."
W. Beuthien and colleagues working at Kantonsspital St. Gallen described "an erythema multiforme-like skin reaction to treatment with the monoclonal anti-TNF-alpha antibody adalimumab in a patient with rheumatoid arthritis."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.